Skip to content
10-Q

Quarterly Report

PARATEK PHARMACEUTICALS, INC.

0001628280-23-016814

← back to feed
Filed
May 9, 2023 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 30, 2023 57.28M sh
Shares Diluted Q1 2023 · Mar 31, 2023 56.9M sh
Shares Diluted Q1 2023 · Mar 31, 2022 52.15M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 $11.09M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$19.11M
Long Term Debt Q1 2023 · Mar 31, 2023 $257.7M
Long Term Debt Q1 2023 · Dec 31, 2022 $256.95M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $45.03M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $34.25M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $49.03M
Stockholders Equity Q1 2023 · Mar 31, 2023 −$189.04M
Stockholders Equity Q1 2023 · Dec 31, 2022 −$171.04M
Stockholders Equity Q1 2023 · Mar 31, 2022 −$140.3M
Stockholders Equity Q1 2023 · Dec 31, 2021 −$127.79M
Current Liabilities Q1 2023 · Mar 31, 2023 $32.75M
Current Liabilities Q1 2023 · Dec 31, 2022 $37.39M
Total Liabilities Q1 2023 · Mar 31, 2023 $339.87M
Total Liabilities Q1 2023 · Dec 31, 2022 $343.58M
Current Assets Q1 2023 · Mar 31, 2023 $111.01M
Current Assets Q1 2023 · Dec 31, 2022 $136.84M
Total Assets Q1 2023 · Mar 31, 2023 $150.83M
Total Assets Q1 2023 · Dec 31, 2022 $172.54M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.35
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.35
Eps Basic Q1 2023 · Mar 31, 2023 −$0.35
Eps Basic Q1 2023 · Mar 31, 2022 −$0.35
Sga Expense Q1 2023 · Mar 31, 2023 $33.49M
Sga Expense Q1 2023 · Mar 31, 2022 $27.6M
Net Income Q1 2023 · Mar 31, 2023 −$20.14M
Net Income Q1 2023 · Mar 31, 2022 −$17.91M
Operating Income Q1 2023 · Mar 31, 2023 −$15.81M
Operating Income Q1 2023 · Mar 31, 2022 −$13.71M
Cost Of Revenue Q1 2023 · Mar 31, 2023 $6.24M
Cost Of Revenue Q1 2023 · Mar 31, 2022 $3.49M
Revenue Q1 2023 · Mar 31, 2023 $31.24M
Revenue Q1 2023 · Mar 31, 2022 $24.86M